At the heart of this research lies augmin, a protein complex integral to the formation of microtubule branches within cells. Microtubules are dynamic, tubular structures that compose part of the cell’s cytoskeleton—the internal scaffold that maintains cell shape and facilitates key intracellular processes. During cell division, the cytoskeleton must organize into a spindle apparatus, a sophisticated structure that aligns and segregates chromosomes to daughter cells, ensuring genetic fidelity. Augmin plays an essential role in nucleating new microtubules from existing ones, creating a branched network that stabilizes the spindle and allows efficient chromosome separation.

Although augmin’s significance in animal cells has been recognized since 2007, its presence and function in plants have remained comparatively enigmatic until recent years. In 2011, researchers at UC Davis discovered eight genes encoding the augmin complex in Arabidopsis thaliana, a model organism central to plant genetic studies. Remarkably, these plant augmin proteins share extensive structural similarity with their human counterparts, underscoring a conserved evolutionary strategy for spindle assembly across kingdoms.

One of the most striking revelations from this work is the dual role of augmin in plants. Beyond its canonical function in cell division, plant augmin orchestrates the microtubule scaffold that directs the architecture and expansion of the plant cell wall. This is particularly significant because plant cells are encased in a rigid cellulose wall that must grow precisely to shape entire organs and ultimately influence crop yield and quality. The cytoskeletal scaffold dictates where enzymatic machinery deposits cellulose, making augmin critical not only for cell proliferation but also for morphogenesis.

Intriguingly, experimental reduction of augmin levels in plant cells results in a disorganized and fragile microtubule network. This fragility translates into malformed cells and stunted growth, visible even at the whole-plant level. For example, Arabidopsis plants with defective augmin are dwarfed compared to healthy controls. Such defects illustrate why certain herbicides, like oryzalin, which disrupt microtubule dynamics, exert their phytotoxic effects by targeting this cytoskeletal infrastructure.

The study’s technological tour de force involved applying cryogenic electron microscopy (Cryo-EM) to capture thousands of detailed images of the extracted plant augmin complex. By flash-freezing samples to nearly -196°C, the researchers preserved the protein’s native conformation long enough to reconstruct a high-resolution three-dimensional structure. These images revealed that augmin resembles a pitchfork, with distinct domains that mediate its assembly and its interaction with microtubules, including regions responsible for binding the nucleation factor NEDD1.

Elucidating the coiled-coil assembly and antiparallel dimerization characteristic of the plant augmin complex provides critical insights into how microtubule branching is initiated and stabilized. Such structural understanding transcends botanical relevance, as aberrations in human augmin subunits have been linked to various malignancies, including aggressive forms of liver and brain cancers, and to infertility. Deciphering augmin’s architecture could therefore fuel the development of novel therapeutic strategies targeting spindle assembly defects in diseased human cells.

Furthermore, the discovery carries implications for agricultural innovation. Microtubule scaffolding guided by augmin influences key agricultural traits, such as cell elongation in rice grains and fiber expansion in cotton. The dramatic cellular elongation involved—sometimes thousands of times the original size—is vital for crop quality and yield. By manipulating augmin activity, scientists may be able to breed novel plant varieties with optimized shapes, sizes, and resilience, thus enhancing food security.

The realization that a common protein complex underpins such diverse biological phenomena—from the growth of banana bends to the proliferation of cancer cells—highlights the interconnectedness of life’s molecular machinery. According to the lead structural biologist involved in the study, Jawdat Al-Bassam, this research exemplifies a “labor of love” that required an interdisciplinary team working at the frontier of molecular and cellular biology.

The comprehensive study also represents a successful example of collaborative science. Postdoctoral fellow Md Ashaduzzaman spearheaded the Cryo-EM imaging while combing through the immense data to assemble the protein’s complex structure. The project benefited from UC Davis’s state-of-the-art Biological Electron Microscopy Campus Core, enabling the high-resolution observations that were previously unattainable.

Additionally, the research draws upon the expertise of other contributors spanning institutions, including Johns Hopkins University and the University of Texas at Dallas. Their combined efforts deliver a unified picture of augmin’s function and form across biological systems, setting a new benchmark for integrative structural biology.

Looking forward, the elucidation of augmin’s architecture offers fertile ground for medical and agricultural research. In medicine, it propels the quest to understand how spindle assembly defects contribute to infertility and oncogenesis, presenting new biomarkers and drug targets. In agriculture, it informs genetic engineering approaches aimed at tailoring plant shapes and improving stress tolerance, ultimately benefiting farmers and consumers worldwide.

This pioneering research not only deepens our fundamental understanding of cellular scaffolds but also illuminates the profound evolutionary conservation that links plant physiology with human health. As the molecular mysteries of augmin are unraveled, the promise of transforming biological insights into tangible therapies and crops edges closer to reality.

Subject of Research:
Not applicable

Article Title:
Cryo-EM structures of plant Augmin reveal coiled-coil assembly, antiparallel dimerization, and NEDD1 binding.

News Publication Date:
12-Dec-2025

Web References:
https://www.nature.com/articles/s41467-025-66332-4

Image Credits:
Liu lab, UC Davis

Keywords:
Structural biology, Plant sciences, Cell biology, Cell division

Xiao, a professor spanning the fields of chemistry, bioengineering, and biosciences, serves as the director of Rice Synthesis X (SynthX), an innovative center uniting chemical biology, nanomaterial synthesis, and organic chemistry to accelerate therapeutic development. His research trajectory focuses on the design and development of chemical tools that interrogate and manipulate biological systems with precision, aiming to translate these discoveries into clinically relevant therapies. Xiao’s team works at the intersection of synthetic chemistry and biology to create molecular entities capable of guiding therapeutic action with specificity and efficiency.

Central to Xiao’s scientific endeavors is his pioneering approach to cancer therapy. By integrating principles from synthetic chemistry, molecular biology, and immunology, he has engineered therapeutic strategies that target tumor microenvironments and metastatic niches. Notably, his research team has introduced a bone-targeting antibody therapy that represents a paradigm-shifting approach, enabling the delivery of biologics specifically to bone tumors and metastases. This innovative concept of skeleton-targeted therapeutics has broad implications for metastatic cancers, notably breast and prostate cancer, where bone metastasis significantly worsens prognosis.

In addition to this breakthrough, Xiao uncovered a novel glyco-immune checkpoint within the bone metastatic niche. This discovery revealed a mechanism by which tumor cells exploit glycosylation patterns to create an immunosuppressive milieu, thereby evading immune-mediated destruction. By targeting and blocking this checkpoint, Xiao’s research demonstrates the ability to reprogram the tumor microenvironment, restoring immunotherapy sensitivity and improving therapeutic outcomes. This work has provided new insights into immune regulation within metastatic cancer and has shaped the development of next-generation immunomodulatory therapies.

The translational impact of Xiao’s work is further evidenced by the founding of OsteoLogic Therapeutics in 2022, a venture dedicated to advancing skeleton-targeted drug delivery systems. Supported by forward-thinking venture entities such as Curie.Bio, Pillar VC, and New York Ventures, OsteoLogic is actively developing therapies that selectively target bone metastases from breast and prostate cancers, aiming to mitigate disease progression and enhance patient quality of life. The company’s platform leverages the molecular principles elucidated in Xiao’s research, emphasizing targeted delivery and immune modulation.

SynthX, under Xiao’s leadership, harnesses multidisciplinary collaborations spanning chemical biology, nanotechnology, and cancer immunology to drive innovative therapeutic solutions. The center has cultivated significant partnerships with top-tier institutions in the Texas Medical Center, including Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center, Houston Methodist, and the University of Texas MD Anderson Cancer Center. These alliances foster a vibrant ecosystem for translational research, accelerating the bench-to-bedside pipeline for novel cancer therapeutics.

Xiao’s laboratory focuses on developing novel molecular building blocks that enhance the functional specificity and efficacy of chemical-biological tools. Through sophisticated synthetic methodologies, his team delivers molecules capable of modifying cellular pathways with unprecedented precision. These innovations allow for the modulation of pathogenic processes underlying cancer, autoimmunity, and metabolic diseases. His research strategy integrates glycobiology and cancer immunology, fields that illuminate the complex interactions governing disease progression and therapeutic response.

The scientific community has recognized Xiao’s integrated approach to merging fundamental chemistry with biological complexity as transformative. His ability to engineer molecules that serve both as probes and therapeutic agents exemplifies the power of chemical biology in solving intricate biomedical challenges. The tools developed in his lab not only elucidate cellular mechanisms but also serve as blueprints for designing next-generation medicines.

Central to Xiao’s vision is the concept of leveraging synthetic chemistry to engineer smarter, more targeted therapeutics that minimize off-target effects and improve patient outcomes. His team employs cutting-edge synthetic techniques to generate molecular entities with tailored functionalities that can navigate the sophisticated landscapes of tumor microenvironments. This strategy enhances drug efficacy while reducing undesirable systemic toxicity, a perennial challenge in cancer therapy.

The discovery of the glyco-immune checkpoint is illuminating new modalities in immunotherapy, showcasing how carbohydrate-mediated interactions within the tumor niche can regulate immune cell activity. By unraveling these complex biochemical pathways, Xiao’s work is pioneering novel checkpoint blockade strategies that complement and potentially overcome resistance to existing immunotherapies, heralding a new chapter in cancer modulation.

Xiao’s innovative approach extends beyond cancer to encompass autoimmune and metabolic disorders, deploying his chemical biology expertise to modulate cellular behavior in diverse pathological contexts. His translational research is rooted in understanding how chemical agents can be harnessed to restore normal cellular function or selectively eliminate diseased cells, broadening the impact of his work across multiple domains of medicine.

In conclusion, Han Xiao’s award acknowledges his leadership in medicinal chemistry and chemical biology, exemplified by his pioneering development of bone-targeted biologics and glyco-immune checkpoint inhibitors. His work epitomizes the synthesis of chemical innovation with biomedical application, driving forward the frontiers of therapeutic discovery with the promise of more precise and effective treatments across oncology and beyond.

Subject of Research: Medicinal chemistry and translational chemical biology focused on cancer therapeutics and immune modulation

Article Title: Rice’s Han Xiao Honored with David W. Robertson Award for Excellence in Medicinal Chemistry

News Publication Date: Not explicitly provided; award ceremony scheduled for March 24, 2026

Web References:

• https://profiles.rice.edu/faculty/han-xiao
• https://synthx.rice.edu/
• https://news.rice.edu/news/2021/drug-doubles-down-bone-cancer-metastasis
• https://news.rice.edu/news/2024/rice-study-unlocks-breakthrough-breast-cancer-bone-metastases

Image Credits: Courtesy of Rice University

Keywords: Medicinal chemistry, chemical biology, cancer therapy, bone metastasis, glyco-immune checkpoint, synthetic chemistry, immunotherapy, molecular biology, bioengineering, translational research, cancer immunology, bone-targeted biologics